| Lauren Michelle Madigan, | |
|
4a330 School Of Medicine 30 North 1900 East, Salt Lake City, UT 84132-0001 | |
| (801) 581-2955 | |
| Not Available |
| Full Name | Lauren Michelle Madigan |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 4a330 School Of Medicine 30 North 1900 East, Salt Lake City, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962744029 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 10726671-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Division University Of Utah Medical Center | 9638073497 | 61 |
| Dermatology Division University Of Utah Medical Center | 9638073497 | 61 |
News Archive
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
› Verified 6 days ago
| Entity Name | Dermatology Division University Of Utah Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922096114 PECOS PAC ID: 9638073497 Enrollment ID: O20031122000107 |
News Archive
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
› Verified 6 days ago
| Entity Name | Moab Valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770513236 PECOS PAC ID: 2466361720 Enrollment ID: O20040114000346 |
News Archive
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
› Verified 6 days ago
| Entity Name | Moab Valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1770513236 PECOS PAC ID: 2466361720 Enrollment ID: O20061104000120 |
News Archive
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Michelle Madigan, 4a330 School Of Medicine 30 North 1900 East, Salt Lake City, UT 84132-0001 Ph: (801) 581-2955 | Lauren Michelle Madigan, 4a330 School Of Medicine 30 North 1900 East, Salt Lake City, UT 84132-0001 Ph: (801) 581-2955 |
News Archive
The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
› Verified 6 days ago
Caitlin Marie Bolender, MD Dermatology Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4a330, Salt Lake City, UT 84132 Phone: 801-581-5509 | |
Dr. Lana Ngoc Pho, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-587-6340 Fax: 801-587-6346 | |
Justin F Thulin, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1151 E 3900 S, Parkview Building B 259, Salt Lake City, UT 84124 Phone: 801-266-7325 Fax: 801-281-2263 | |
Bahman Sotoodian, MD, FRCP(C), FAAD Dermatology Medicare: Medicare Enrolled Practice Location: 440 W 200 S Ste 250, Salt Lake City, UT 84101 Phone: 801-595-1600 | |
Amber R. Jimenez, MD Dermatology Medicare: Medicare Enrolled Practice Location: 30 N 1900 E # 4a330, Salt Lake City, UT 84132 Phone: 015-816-4658 | |
Dr. Douglas L Powell, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2955 | |
David A Wada, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr # E13, Salt Lake City, UT 84132 Phone: 801-581-2955 |